Shared Mitochondrial Pathways Identified Across 23 Neurodevelopmental Risk Genes

Decoding the Genetic Heterogeneity of Neurodevelopmental Disorders

The clinical landscape of neurodevelopmental disorders is defined by a frustrating paradox. While patients often present with overlapping symptoms such as impaired social communication and sensory processing, the underlying genetic drivers are remarkably diverse [1, 2]. Hundreds of rare variants in genes governing chromatin accessibility (the physical state of DNA that allows or restricts access for gene expression) and synaptic scaffolding have been implicated in conditions ranging from autism to severe intellectual disability [3, 4]. For instance, mutations in SHANK3, which encodes a scaffold protein at the post-synaptic density of glutamatergic synapses, are present in up to 2.12% of patients with moderate to profound intellectual disability [4]. This heterogeneity complicates diagnosis and leaves many patients without targeted therapeutic options, as most current treatments only address secondary symptoms rather than primary pathology [5, 6]. Understanding how these disparate genetic insults might converge on common biological pathways is essential for moving toward more effective, mechanism-based interventions [7]. A recent study now offers fresh insights into these molecular intersections by mapping the shared effects of dozens of risk genes across human neural cell types.

Mapping Molecular Convergence Across Human Neural Cell Types

To investigate how disparate genetic mutations result in similar clinical presentations, researchers applied a pooled CRISPR approach (a gene-editing technique that allows for the simultaneous targeting and screening of multiple genes within a single population of cells). This methodology enabled the team to successfully target 23 neurodevelopmental disorder loss-of-function genes specifically involved in chromatin biology, the regulatory system that dictates how the physical structure of DNA affects gene expression. By systematically silencing these genes, the study aimed to identify where the downstream molecular signals of these diverse mutations intersect, potentially revealing shared therapeutic targets for patients with different underlying genotypes. The researchers examined these convergent effects on gene expression across three distinct cell types derived from human induced pluripotent stem cells (adult cells reprogrammed back into an embryonic-like state). These included neural progenitor cells, which are immature cells that can differentiate into various types of neurons; glutamatergic neurons, the primary excitatory cells in the brain; and GABAergic neurons, the primary inhibitory cells. The study found that points of molecular convergence vary between these different cell types, indicating that the pathological impact of chromatin-related mutations is highly dependent on the cellular context and developmental stage of the neuron. For clinicians, this cell-type specificity suggests that a single genetic mutation may disrupt entirely different biological pathways depending on whether it is expressed in an excitatory or inhibitory lineage, complicating the search for a universal treatment.

Glutamatergic Neurons as a Primary Hub of Pathology

The analysis of transcriptomic signatures (the complete set of messenger RNA molecules expressed in a cell) across different stages of cellular maturation revealed that the pathological impact of the 23 targeted risk genes is not uniformly distributed. The researchers observed that the greatest number of convergent genes was found in mature glutamatergic neurons, which form the primary excitatory networks in the human cortex. Furthermore, these mature excitatory cells exhibited the strongest convergent networks compared to neural progenitor cells or inhibitory GABAergic neurons. This finding suggests that while genetic mutations are present from the earliest stages of development, their molecular consequences may become more pronounced and interconnected as neurons reach functional maturity and integrate into cortical circuits. Within these mature glutamatergic neurons, the molecular signals from disparate genetic mutations intersected at three distinct biological hubs. The study identified that convergent pathways broadly represent synaptic pathways, which govern the communication between neurons, and epigenetic pathways, which involve chemical modifications that change gene expression without altering the underlying DNA sequence. Most notably, the researchers found that convergent pathways unexpectedly represent mitochondrial pathways, which are responsible for cellular energy production. For the practicing physician, this intersection suggests that diverse genetic drivers of neurodevelopmental disorders may ultimately result in a common state of metabolic and synaptic dysfunction within excitatory circuits. This shared downstream pathology could explain why patients with different genotypes often present with similar clinical phenotypes, such as altered arousal and sensory processing.

Correlating Molecular Signatures with Clinical Phenotypes

The clinical management of neurodevelopmental disorders is complicated by the sheer variety of identified risk genes. Until now, it has been unclear how these diverse genetic profiles converge on similar biological pathways to produce overlapping clinical phenotypes. To bridge this gap, the researchers investigated whether the molecular signatures observed in their cellular models aligned with established clinical and biological data. The study found that the most convergent networks were observed between neurodevelopmental disorder genes with shared biological annotations, which are standardized classifications of a gene's known functional roles within the cell. This indicates that genes with similar baseline functions are more likely to disrupt the same downstream molecular pathways when they undergo loss-of-function mutations. The researchers further validated these findings by comparing the laboratory data to real-world patient observations and tissue samples. They discovered that the most convergent networks were observed between neurodevelopmental disorder genes with shared clinical associations, meaning that genes linked to similar symptom clusters in patients also showed the highest degree of molecular overlap in the neural models. To ensure these laboratory results mirrored actual human pathology, the authors analyzed gene activity in the human brain. They confirmed that the most convergent networks were observed between neurodevelopmental disorder genes with shared co-expression patterns in human post-mortem brain, a metric that tracks which genes are typically activated together in intact brain tissue. By demonstrating that molecular convergence in the laboratory correlates with both clinical presentations and post-mortem pathology, the study provides a biological explanation for why patients with distinct genetic mutations often exhibit nearly identical neurodevelopmental symptoms.

Pharmacological Reversal of Behavioral Deficits in Zebrafish

After identifying shared molecular pathways across diverse genetic mutations, the researchers sought to determine if these convergence points could serve as viable targets for pharmacological intervention. They utilized the convergent transcriptomic signatures to screen for potential therapeutic agents. By identifying drugs predicted to reverse convergent transcriptomic signatures, the team moved from descriptive genomics to functional rescue. This approach suggests that if multiple genetic mutations lead to a common abnormal gene expression profile, a single drug capable of normalizing that profile might be effective regardless of the specific upstream mutation. To validate these predictions in a living system, the researchers employed zebrafish models carrying mutations in the neurodevelopmental disorder risk genes. They specifically focused on drugs predicted to reverse arousal and sensory processing behaviors, which are common clinical manifestations in patients with these conditions. When administered to the animal models, these drugs ameliorated behavioral phenotypes in zebrafish neurodevelopmental disorder gene mutants. This behavioral rescue suggests that the molecular convergence observed in human neural cells translates into observable functional improvements in living organisms, providing a direct link between cellular pathology and clinical symptoms. The study concludes that the convergent effects of neurodevelopmental disorder risk genes could provide clinically useful insights for diagnosis and treatment. For the practicing clinician, this shift in focus from individual rare mutations to shared downstream pathways offers a practical path forward in managing genetically heterogeneous populations. Rather than developing thousands of gene-specific therapies, targeting the common mitochondrial, synaptic, or epigenetic hubs identified in this research may allow for more broadly applicable pharmacological strategies in the future.

References

1. Jiang C, Lin L, Long S, et al. Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-01081-0

2. Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers. 2015. doi:10.1038/nrdp.2015.20

3. Chen Y, Liang R, Li Y, et al. Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-02030-9

4. Leblond CS, Nava C, Polge A, et al. Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments. PLoS Genetics. 2014. doi:10.1371/journal.pgen.1004580

5. Amiri D, Karlsson B, Briziarelli L. Review of Cell Therapy Approaches to Autism: A Review of Clinical Trial. Journal of Vaccines Immunology and Immunopathology. 2023. doi:10.29011/2575-789x.0001103

6. Cui L, Li S, Wang S, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01738-y

7. Polit LD, Eidhof I, McNeill RV, et al. Recommendations, guidelines, and best practice for the use of human induced pluripotent stem cells for neuropharmacological studies of neuropsychiatric disorders.. Neuroscience applied. 2023. doi:10.1016/j.nsa.2023.101125